Literature DB >> 21173546

Hepatic follicular dendritic cell sarcoma favorably controlled by transcatheter arterial chemoembolization.

Hiroko Tsunemine1, Hiroshi Akasaka, Toshiyuki Kusama, Koji Fujimoto, Arata Motoyama, Katsuyuki Aozasa, Taiichi Kodaka.   

Abstract

A 78-year-old woman with multiple tumors in the liver and spleen was diagnosed with follicular dendritic cell (FDC) sarcoma based on the histological picture of splenectomized specimen and its expression of CD21 and CD 23. As a paraneoplastic immune disorder, Coombs' test was positive although hemolysis was not obvious. Since systemic chemotherapies were ineffective for residual liver tumors, transcatheter arterial chemoembolization (TACE) was performed with subsequent tumor reduction. Currently, the patient is alive 27 months after the diagnosis with residual hepatic tumors favorably controlled by repeated TACE. Our experience suggests that TACE is useful for the management of hepatic FDC sarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 21173546     DOI: 10.2169/internalmedicine.49.3828

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Follicular dendritic cell sarcoma of the liver with metachronous small bowel and splenic metastases: a case report and literature review.

Authors:  Ken Min Chin; Woon Yang Ho; Kiat Hon Tony Lim; Yaw Fui Alexander Chung; Ser Yee Lee
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

2.  Inflammatory pseudotumour-like follicular dendritic cell tumour of the spleen.

Authors:  Raisuke Nishiyama; Satoshi Baba; Yoichi Watahiki; Hirotoshi Maruo
Journal:  BMJ Case Rep       Date:  2015-03-12

Review 3.  Hepatic inflammatory pseudotumor-like follicular dendritic cell tumor with hepatic lymphoma history: A case report and literature review.

Authors:  Jiang Li; Hai-Su Tao; Dong Chen; Zhi-Yong Huang; Er-Lei Zhang
Journal:  Medicine (Baltimore)       Date:  2021-10-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.